The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
<p>Abstract</p> <p>Background</p> <p>Interferon beta (IFNβ) and glatiramer acetate (GA) are administered by subcutaneous (SC) or intramuscular (IM) injection. Patients with multiple sclerosis (MS) often report injection-site reactions (ISRs) as a reason for noncomplianc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-11-01
|
| Series: | BMC Neurology |
| Online Access: | http://www.biomedcentral.com/1471-2377/11/144 |
| _version_ | 1819030959572385792 |
|---|---|
| author | Beer Karsten Müller Martin Hew-Winzeler Anna Bont Adriano Maire Philippe You Xiaojun Foulds Pamela Mårlind Jessica Curtius Daniela |
| author_facet | Beer Karsten Müller Martin Hew-Winzeler Anna Bont Adriano Maire Philippe You Xiaojun Foulds Pamela Mårlind Jessica Curtius Daniela |
| author_sort | Beer Karsten |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Interferon beta (IFNβ) and glatiramer acetate (GA) are administered by subcutaneous (SC) or intramuscular (IM) injection. Patients with multiple sclerosis (MS) often report injection-site reactions (ISRs) as a reason for noncompliance or switching therapies. The aim of this study was to compare the proportion of patients on different formulations of IFNβ or GA who experienced ISRs and who switched or discontinued therapy because of ISRs.</p> <p>Methods</p> <p>The Swiss MS Skin Project was an observational multicenter study. Patients with MS or clinically isolated syndrome who were on the same therapy for at least 2 years were enrolled. A skin examination was conducted at the first study visit and 1 year later.</p> <p>Results</p> <p>The 412 patients enrolled were on 1 of 4 disease-modifying therapies for at least 2 years: IM IFNβ-1a (n = 82), SC IFNβ-1b (n = 123), SC IFNβ-1a (n = 184), or SC GA (n = 23). At first evaluation, ISRs were reported by fewer patients on IM IFNβ-1a (13.4%) than on SC IFNβ-1b (57.7%; <it>P </it>< 0.0001), SC IFNβ-1a (67.9%; <it>P </it>< 0.0001), or SC GA (30.4%; <it>P </it>= not significant [NS]). No patient on IM IFNβ-1a missed a dose in the previous 4 weeks because of ISRs, compared with 5.7% of patients on SC IFNβ-1b (<it>P </it>= 0.044), 7.1% of patients on SC IFNβ-1a (<it>P </it>= 0.011), and 4.3% of patients on SC GA (<it>P </it>= NS). Primary reasons for discontinuing or switching therapy were ISRs or lack of efficacy. Similar patterns were observed at 1 year.</p> <p>Conclusions</p> <p>Patients on IM IFNβ-1a had fewer ISRs and were less likely to switch therapies than patients on other therapies. This study may have implications in selecting initial therapy or, for patients considering switching or discontinuing therapy because of ISRs, selecting an alternative option.</p> |
| first_indexed | 2024-12-21T06:38:26Z |
| format | Article |
| id | doaj.art-8a61f1849cbe4e72b8e757323f6f2856 |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-12-21T06:38:26Z |
| publishDate | 2011-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-8a61f1849cbe4e72b8e757323f6f28562022-12-21T19:12:47ZengBMCBMC Neurology1471-23772011-11-0111114410.1186/1471-2377-11-144The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBeer KarstenMüller MartinHew-Winzeler AnnaBont AdrianoMaire PhilippeYou XiaojunFoulds PamelaMårlind JessicaCurtius Daniela<p>Abstract</p> <p>Background</p> <p>Interferon beta (IFNβ) and glatiramer acetate (GA) are administered by subcutaneous (SC) or intramuscular (IM) injection. Patients with multiple sclerosis (MS) often report injection-site reactions (ISRs) as a reason for noncompliance or switching therapies. The aim of this study was to compare the proportion of patients on different formulations of IFNβ or GA who experienced ISRs and who switched or discontinued therapy because of ISRs.</p> <p>Methods</p> <p>The Swiss MS Skin Project was an observational multicenter study. Patients with MS or clinically isolated syndrome who were on the same therapy for at least 2 years were enrolled. A skin examination was conducted at the first study visit and 1 year later.</p> <p>Results</p> <p>The 412 patients enrolled were on 1 of 4 disease-modifying therapies for at least 2 years: IM IFNβ-1a (n = 82), SC IFNβ-1b (n = 123), SC IFNβ-1a (n = 184), or SC GA (n = 23). At first evaluation, ISRs were reported by fewer patients on IM IFNβ-1a (13.4%) than on SC IFNβ-1b (57.7%; <it>P </it>< 0.0001), SC IFNβ-1a (67.9%; <it>P </it>< 0.0001), or SC GA (30.4%; <it>P </it>= not significant [NS]). No patient on IM IFNβ-1a missed a dose in the previous 4 weeks because of ISRs, compared with 5.7% of patients on SC IFNβ-1b (<it>P </it>= 0.044), 7.1% of patients on SC IFNβ-1a (<it>P </it>= 0.011), and 4.3% of patients on SC GA (<it>P </it>= NS). Primary reasons for discontinuing or switching therapy were ISRs or lack of efficacy. Similar patterns were observed at 1 year.</p> <p>Conclusions</p> <p>Patients on IM IFNβ-1a had fewer ISRs and were less likely to switch therapies than patients on other therapies. This study may have implications in selecting initial therapy or, for patients considering switching or discontinuing therapy because of ISRs, selecting an alternative option.</p>http://www.biomedcentral.com/1471-2377/11/144 |
| spellingShingle | Beer Karsten Müller Martin Hew-Winzeler Anna Bont Adriano Maire Philippe You Xiaojun Foulds Pamela Mårlind Jessica Curtius Daniela The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study BMC Neurology |
| title | The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study |
| title_full | The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study |
| title_fullStr | The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study |
| title_full_unstemmed | The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study |
| title_short | The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study |
| title_sort | prevalence of injection site reactions with disease modifying therapies and their effect on adherence in patients with multiple sclerosis an observational study |
| url | http://www.biomedcentral.com/1471-2377/11/144 |
| work_keys_str_mv | AT beerkarsten theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT mullermartin theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT hewwinzeleranna theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT bontadriano theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT mairephilippe theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT youxiaojun theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT fouldspamela theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT marlindjessica theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT curtiusdaniela theprevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT beerkarsten prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT mullermartin prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT hewwinzeleranna prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT bontadriano prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT mairephilippe prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT youxiaojun prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT fouldspamela prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT marlindjessica prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy AT curtiusdaniela prevalenceofinjectionsitereactionswithdiseasemodifyingtherapiesandtheireffectonadherenceinpatientswithmultiplesclerosisanobservationalstudy |